William Blair analyst Matt Phipps has maintained their bullish stance on INSM stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors related to Insmed’s late-stage pipeline and expansion opportunities. He views the ENCORE Phase IIIb results for Arikayce in newly diagnosed MAC lung disease as a strong validation of the drug’s efficacy, noting statistically meaningful gains in culture conversion and symptom relief that support broad first-line use.
Phipps also highlights the strategic upside from TPIP in idiopathic pulmonary fibrosis, where recent Tyvaso data in the TETON program provide a favorable benchmark that TPIP could potentially surpass with once-daily dosing. With regulatory submissions for Arikayce in the U.S. and Japan targeted for 2026 and pivotal TPIP trials planned in IPF and PPF, he believes Insmed is positioned for significant long-term growth that justifies a Buy recommendation.
Phipps covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Insmed, and Evommune, Inc.. According to TipRanks, Phipps has an average return of 3.6% and a 42.86% success rate on recommended stocks.
In another report released today, UBS also maintained a Buy rating on the stock with a $166.00 price target.